| 262.75 -1.32 (-0.5%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 325.45  |
1-year : | 337.04 |
| Resists | First : | 278.64 |
Second : | 288.57 |
| Pivot price | 270.48 |
|||
| Supports | First : | 262.57 |
Second : | 218.46 |
| MAs | MA(5) : | 265.05 |
MA(20) : | 272.96 |
| MA(100) : | 284.98 |
MA(250) : | 262.64  |
|
| MACD | MACD : | -4.3 |
Signal : | -3.7 |
| %K %D | K(14,3) : | 3.5 |
D(3) : | 5.4 |
| RSI | RSI(14): 33.9 |
|||
| 52-week | High : | 329.72 | Low : | 211.71 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AMGN ] has closed above bottom band by 18.9%. Bollinger Bands are 1.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 266.43 - 267.95 | 267.95 - 269.59 |
| Low: | 258.29 - 259.99 | 259.99 - 261.83 |
| Close: | 259.57 - 262.5 | 262.5 - 265.68 |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Thu, 18 Apr 2024
Federated Hermes Inc. Sells 760,949 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Thu, 18 Apr 2024
William Blair Comments on Amgen Inc.'s Q1 2024 Earnings (NASDAQ:AMGN) - MarketBeat
Wed, 17 Apr 2024
Amgen Inc Says CEO Robert Bradway's 2023 Total Compensation Was $22.6 Million Versus $21.4 Million In 2022 ... - XM
Wed, 17 Apr 2024
Amgen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Tue, 16 Apr 2024
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Mon, 15 Apr 2024
"AI Generated Business & Earnings News" Amgen Inc. (AMGN) Goldman Sachs 44th Annual Global Healthcare ... - imdb
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 536 (M) |
| Shares Float | 534 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 80.7 (%) |
| Shares Short | 10,470 (K) |
| Shares Short P.Month | 11,020 (K) |
| EPS | 12.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.64 |
| Profit Margin | 23.8 % |
| Operating Margin | 8.1 % |
| Return on Assets (ttm) | 6.2 % |
| Return on Equity (ttm) | 135.7 % |
| Qtrly Rev. Growth | 19.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 52.6 |
| EBITDA (p.s.) | 22.82 |
| Qtrly Earnings Growth | -52.5 % |
| Operating Cash Flow | 8,470 (M) |
| Levered Free Cash Flow | 3,120 (M) |
| PE Ratio | 21.05 |
| PEG Ratio | 2.7 |
| Price to Book value | 22.57 |
| Price to Sales | 4.99 |
| Price to Cash Flow | 16.62 |
| Dividend | 2.25 |
| Forward Dividend | 0 |
| Dividend Yield | 0.8% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|